Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053.
Article
PubMed
Google Scholar
Laakso M: Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med. 2001, 249: 225-235. 10.1046/j.1365-2796.2001.00789.x.
Article
CAS
PubMed
Google Scholar
Herlitz J, Malmberg K, Karlson BW, Ryden L, Hjalmarson A: Mortality and morbidity during a five-year follow-up of diabetics with myocardial infarction. Acta Med Scand. 1988, 224: 31-38.
Article
CAS
PubMed
Google Scholar
Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L: Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003, 24: 838-844. 10.1016/S0195-668X(02)00828-X.
Article
PubMed
Google Scholar
Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB: Mortality among diabetics in a national sample. Am J Epidemiol. 1988, 128: 389-401.
CAS
PubMed
Google Scholar
Haffner SM: Statin therapy for the treatment of diabetic dyslipidemia. Diabetes Metab Res Rev. 2003, 19: 280-287. 10.1002/dmrr.393.
Article
CAS
PubMed
Google Scholar
Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K: Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J. 1998, 19: 1434-1503. 10.1053/euhj.1998.1243.
Article
Google Scholar
European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999, 16: 716-730. 10.1046/j.1464-5491.1999.00166.x.
Article
Google Scholar
De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, Orth-Gomer K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, European Society of Cardiology Committee for Practice Guidelines: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2003, 10 (Suppl 1): S1-S78.
Article
PubMed
Google Scholar
American Diabetes Association: Management of dyslipidemia with diabetes. Diabetes Care. 2002, 25 (Suppl 1): S74-S77.
Google Scholar
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.
Article
Google Scholar
Scandinavian Simvastatin Survival Study (4S): Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994, 344: 1383-1389.
Google Scholar
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995, 333: 1301-1307. 10.1056/NEJM199511163332001.
Article
CAS
PubMed
Google Scholar
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996, 335: 1001-1009. 10.1056/NEJM199610033351401.
Article
CAS
PubMed
Google Scholar
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998, 339: 1349-1357. 10.1056/NEJM199811053391902.
Article
Google Scholar
Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998, 279: 1615-1622. 10.1001/jama.279.20.1615.
Article
CAS
PubMed
Google Scholar
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003, 361: 1149-1158. 10.1016/S0140-6736(03)12948-0.
Article
CAS
PubMed
Google Scholar
Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997, 20: 614-620.
Article
PubMed
Google Scholar
Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation. 1998, 98: 2513-2519.
Article
CAS
PubMed
Google Scholar
Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A, LIPID Study Group: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003, 26: 2713-2721.
Article
CAS
PubMed
Google Scholar
Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003, 361: 2005-2016. 10.1016/S0140-6736(03)12475-0.
Article
PubMed
Google Scholar
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004, 364: 685-696. 10.1016/S0140-6736(04)16895-5.
Article
CAS
PubMed
Google Scholar
del Canizo-Gomez FJ, Moreira-Andres MN: Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines?. Diabetes Res Clin Pract. 2004, 65: 125-133. 10.1016/j.diabres.2003.12.002.
Article
PubMed
Google Scholar
Betteridge JD, Leiter LA, AUDIT Investigators: The AUDIT Study: regional variations in physicians attitudes to diabetic dyslipidaemia. Diabetologia. 2004, 47 (Suppl 1): A73.
Google Scholar
Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR) trial. Am J Cardiol. 2003, 92: 152-160. 10.1016/S0002-9149(03)00530-7.
Article
CAS
PubMed
Google Scholar
Kritharides L: Reducing low-density lipoprotein cholesterol – treating to target and meeting new European goals. Eur Heart J. 2004, 6 (Suppl A): A1-A7.
Google Scholar
Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, Hutchinson H: Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol. 2002, 89: 268-275. 10.1016/S0002-9149(01)02226-3.
Article
CAS
PubMed
Google Scholar
Olsson AG, Istad H, Luurila O, Ose L, Stender S, Tuomilehto J, Wiklund O, Southworth H, Pears J, Wilpshaar JW, Rosuvastatin Investigators Group: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am Heart J. 2002, 144: 1044-1051. 10.1067/mhj.2002.128049.
Article
CAS
PubMed
Google Scholar
Strandberg TE, Feely J, Sigurdsson EL: Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: A DISCOVERY study. Clin Therapeut. 2004, 26: 1821-1833. 10.1016/j.clinthera.2004.11.015.
Article
CAS
Google Scholar
Schuster H, Fox JC: Investigating cardiovascular risk reduction – the rosuvastatin GALAXY programme. Expert Opin Pharmacother. 2004, 5: 1187-1200.
Article
CAS
PubMed
Google Scholar
Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A, Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group: Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004, 147: 705-713. 10.1016/j.ahj.2003.10.004.
Article
CAS
PubMed
Google Scholar
Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS:23). BMJ. 1998, 316: 823-828.
Article
PubMed Central
CAS
PubMed
Google Scholar
Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab. 2003, 5 (Suppl 1): S19-27. 10.1046/j.1462-8902.2003.0310.x.
Article
CAS
PubMed
Google Scholar
Gudbjörnsdottir S, Cederholm J, Nilsson PM, Eliasson B, Steering Committee of the Swedish National Diabetes Register: The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003, 26: 1270-1276.
Article
PubMed
Google Scholar
Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ, National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004, 110: 227-239. 10.1161/01.CIR.0000133317.49796.0E.
Article
PubMed
Google Scholar
Pearson TA, Laurora I, Chu H, Kafonek S: The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000, 160: 459-467. 10.1001/archinte.160.4.459.
Article
CAS
PubMed
Google Scholar
EUROASPIRE II Study Group: Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J. 2001, 22: 554-572. 10.1053/euhj.2001.2610.
Article
Google Scholar
Foley KA, Simpson RJ, Crouse JR, Weiss TW, Markson LE, Alexander CM: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003, 92: 79-81. 10.1016/S0002-9149(03)00474-0.
Article
CAS
PubMed
Google Scholar
Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003, 348: 383-393. 10.1056/NEJMoa021778.
Article
PubMed
Google Scholar
Olsson AG, McTaggart F, Raza A: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev. 2002, 20: 303-328.
Article
CAS
PubMed
Google Scholar
Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001, 358: 2026-2033. 10.1016/S0140-6736(01)07098-2.
Article
CAS
PubMed
Google Scholar
Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, Atzeni MM, Melis MG, Maioli M: Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care. 1997, 20: 1891-1895.
Article
CAS
PubMed
Google Scholar
Nakamura T, Ushiyama C, Hirokawa K, Osada S, Shimada N, Koide H: Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia. Am J Nephrol. 2001, 21: 449-454. 10.1159/000046648.
Article
CAS
PubMed
Google Scholar
Rosenson RS: Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther. 2003, 1: 495-505. 10.1586/14779072.1.4.495.
Article
CAS
PubMed
Google Scholar